Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
TEMPLE CITY, Calif., Feb. 27, 2017 -- Fulgent Genetics, Inc. (NASDAQ:FLGT) today announced that Ming Hsieh, Chairman and Chief Executive Officer, and Paul Kim, Chief Financial Officer, are scheduled to participate in the 2017 BTIG Medical Technology, Life Science and Diagnostic Tools Conference on Wednesday, March 1, 2017 in Snowbird, Utah.
BTIG’s annual conference consists of a series of one-on-one meetings and will not be webcast.
About Fulgent Genetics
Fulgent Genetics is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes more than 18,000 single-gene tests and more than 300 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Investor Relations Contacts: The Blueshirt Group Nicole Borsje, 415-217-2633, [email protected] Chris Danne, 415-217-5865, [email protected]
